Postmenopausal women with ER positive, HER-2 negative, locally advanced breast cancer were enrolled in the NEOLETEXE-trial and randomized to sequential treatment starting with either letrozole (2.5 mg o.d.)or exemestane (25 mg o.d.)followed by the alternative aromatase inhibitor. The gene discussed is ESR1; the disease is breast carcinoma.